货号:A330804 同义名: ABT-378;A-157378.0
Lopinavir(ABT-378)是一种高效选择性的HIV-1蛋白酶抑制剂,对野生型和突变型HIV蛋白酶的Ki值在1.3至3.6 pM之间。其作用是阻止HIV-1的成熟,从而阻止其感染性。Lopinavir还表现出对SARS-CoV 3CLpro的抑制作用,IC50为14.2 μM。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | HIV Protease ↓ ↑ | HIV-1 caspid ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dextran sulfate sodium, mw 40,000 | ✔ | M.W 40000 | |||||||||||||||||
Vicriviroc maleate | ✔ | 98+% | |||||||||||||||||
Rosamultin | ✔ | 97% | |||||||||||||||||
Darunavir | ✔ | 98% | |||||||||||||||||
Lopinavir |
++++
HIV protease, Ki: 1.3 pM |
99+% | |||||||||||||||||
Chloroquine | ✔ | Autophagy | 95% | ||||||||||||||||
Amprenavir |
+
HIV protease, IC50: 14.6 ng/mL |
PXR | 99%+ | ||||||||||||||||
NBD-556 | ✔ | 99%+ | |||||||||||||||||
Nelfinavir Mesylate |
+++
HIV protease, Ki: 2 nM |
99%+ | |||||||||||||||||
Atazanavir Sulfate | ✔ | 98% | |||||||||||||||||
Limonin | ✔ | 98% | |||||||||||||||||
Saquinavir |
++
HIV proteinase, IC50: 2.7 nM |
98% | |||||||||||||||||
Ritonavir | ✔ | 98% | |||||||||||||||||
Azvudine | ✔ | 98% | |||||||||||||||||
Lenacapavir |
++++
HIV-1 capsid, EC50: 0.1 nM |
97% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
靶点 |
|
描述 | Lopinavir (ABT-378) is an antiretroviral of the HIV protease inhibitor class, as well as an inhibitor of P-Glycoprotein, Cytochrome P450 3A and Organic Anion Transporting Polypeptide 1B1. It has a mean oral bioavailability of less than 20 % due to extensive hepatic metabolism by cytochrome P450 3A4. The reported half-life of Lopinavir is 5-6 hours and the maximum recommended daily dose is 400 mg/day[3]. In a randomised controlled trial done in HIV-infected adults or adolescents, at 144 weeks, 86% participants in the protease inhibitor plus nucleoside reverse-transcriptase inhibitor (NRTI) group (lopinavir 400 mg with ritonavir 100 mg, twice per day plus two or three clinician-selected NRTIs) had viral loads of less than 400 copies per mL compared with 81% in the protease inhibitor plus raltegravir (400 mg twice per day) group[4]. Promastigotes of L. amazonensis (the cause of tropical disease Leishmaniasis) treated with increasing concentrations of lopinavir (7.5, 15 and 30 µM) exhibited accumulation of lipid inclusions and increased amounts of cholesterol-ester in a dose-dependent manner, which reinforced that lopinavir can be useful in leishmaniasis treatment[5]. In Human Glioblastoma U-87 MG cell line, co-treatment with Lopinavir and Ritonavir (25 and 50 µM) for 24 h promoted a significant increase in ROS production, caused mitochondrial network damage and induced apoptosis in a caspase-independent manner[6]. In the latest study, Lopinavir was found to have anti-2019-novel coronavirus activity. |
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
HEK293 cells | Function assay | 48 h | Antiviral activity against wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay, EC50=0.0028 μM | 17638694 | |
human MT4 cells | Function assay | 5 days | Antiviral activity against HIV2 MS infected in human MT4 cells assessed as inhibition of virus production after 5 days by Lenti-RT activity assay, EC50=0.006 μM | 17576848 | |
human PBMC cells | Function assay | 5 days | Antiviral activity against HIV2 MS infected in human PBMC cells assessed as inhibition of virus production after 5 days by Lenti-RT activity assay, EC50=0.015 μM | 17576848 | |
MT2 cells | Function assay | Antiviral activity against HIV2 EHO in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay, EC50=0.0026 μM | 17371811 | ||
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00661349 | HIV Infections | Phase 4 | Terminated(It has been impossi... 展开 >>ble to achieve the number of patients defined by protocol) 收起 << | - | Spain ... 展开 >> Hospital Son Dureta Palma de Mallorca, Baleares, Spain, 07014 H.U. Germans Trias i Pujol - Unitat VIH, Fundació Lluita contra la Sida Badalona, Barcelona, Spain, 08916 Hospital General Universitario de Alicante Alicante, Spain, 03010 Hospital Clínic i Provincial de Barcelona Barcelona, Spain, 08036 Hospital Universitario Príncipe de Asturias Madrid, Spain, 28005 Hospital Clínico San Carlos Madrid, Spain, 28040 Hospital Universitario la Paz Madrid, Spain, 28046 Hospital Clínico de Salamanca Salamanca, Spain, 37007 Hospital Universitario de Valme Sevilla, Spain, 41014 收起 << |
NCT00262522 | Human Immunodeficiency Virus I... 展开 >>nfections 收起 << | Phase 3 | Completed | - | - |
NCT00105079 | HIV Infections | Phase 3 | Completed | - | - |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.59mL 0.32mL 0.16mL |
7.95mL 1.59mL 0.80mL |
15.90mL 3.18mL 1.59mL |
CAS号 | 192725-17-0 |
分子式 | C37H48N4O5 |
分子量 | 628.801 |
别名 | ABT-378;A-157378.0;Koletra;Aluviran |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Sealed in dry,2-8°C |
溶解度 |
DMSO: 250 mg/mL(397.58 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |
30% PEG400+0.5% Tween80+5% propylene glycol+water 30 mg/mL suspension |